Gilead, LEO Pharma
Gilead roars into JPM25, inking a $1.7B inflammation deal with Leo Pharma
Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma on the eve of the J.P. Morgan Healthcare conference.
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...
Leo Pharma, meanwhile, announced this fall that it had submitted its delgocitinib cream for FDA approval as a treatment for adults with moderate to severe CHE for whom topical corticosteroids ...
Hosted on MSN1mon
LEO Pharma’s eczema cream gains MHRA marketing authorisationLEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, Anzupgo (delgocitinib ...
Vice president and general manager of UK & Ireland at LEO Pharma, Sarah Kleinpeter, said: “We are pleased that adolescents between 12-17 years of age living with atopic dermatitis will now have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback